C-Peptide Stimulation by Glucagon

The C-Peptide Stimulation by Glucagon test is a specialised dynamic blood test used to assess how much insulin the pancreas can still produce. It measures the concentration of C-peptide before and after the administration of glucagon under medical supervision. Glucagon temporarily stimulates the pancreatic beta cells, allowing the doctor to evaluate the body's remaining insulin-producing capacity, also called pancreatic beta-cell reserve.

Insulin is produced inside the pancreas as part of a larger molecule called proinsulin. When proinsulin is divided, insulin and C-peptide are released into the bloodstream in approximately equal amounts. Insulin is rapidly processed by the liver and may also be affected by injected insulin therapy. C-peptide remains in the circulation longer and is not present in pharmaceutical insulin. Measuring C-peptide can therefore provide a useful indication of the insulin being produced naturally by the patient's pancreas.

A routine fasting C-peptide result provides information at one point in time. However, some patients may have a low or borderline fasting result even though their pancreas can still respond when appropriately stimulated. The glucagon-stimulated test helps reveal this reserve by comparing baseline and post-stimulation C-peptide concentrations. Doctors may use the findings alongside blood glucose, HbA1c, fasting C-peptide, insulin, pancreatic autoantibodies and the patient's clinical history.

Benefits of the Test

The glucagon-stimulated C-peptide test gives doctors functional information about the pancreatic beta cells. This can be particularly useful when the type of diabetes is uncertain, when insulin treatment requirements are being assessed or when a patient's remaining natural insulin secretion needs to be estimated.

• Evaluates the pancreas's ability to produce insulin after stimulation.
• Helps estimate the remaining functional beta-cell reserve.
• Supports differentiation between severe insulin deficiency and preserved insulin secretion.
• May assist in evaluating people with an uncertain classification of diabetes.
• Can contribute to treatment planning when interpreted by an endocrinologist or physician.
• Provides information that is generally not affected by injected insulin.
• May be useful when a fasting C-peptide result is low, borderline or difficult to interpret.
• Can support the assessment of patients with suspected type 1 diabetes, type 2 diabetes or other forms of diabetes.

The result should never be used as the only basis for diagnosing diabetes or changing medication. C-peptide values are influenced by blood glucose at the time of collection, kidney function, recent food intake, medicines and the laboratory method. A complete interpretation requires clinical correlation.

Why Doctors Recommend This Test

A doctor may recommend this test when it is necessary to determine whether the pancreas retains a meaningful capacity to secrete insulin. In type 1 diabetes, autoimmune destruction of beta cells commonly results in markedly reduced insulin production. In type 2 diabetes, insulin production may initially be preserved or increased but can decline as the condition progresses. Other forms of diabetes, including monogenic diabetes, pancreatic disease-related diabetes and latent autoimmune diabetes in adults, may require additional investigation.

The test may be considered when the clinical presentation does not clearly match a single diabetes category. Examples include an adult diagnosed with diabetes who rapidly becomes insulin-dependent, a person diagnosed at a young age without typical autoimmune findings, or a patient whose insulin requirements appear inconsistent with other laboratory results. It may also be used in selected research, specialist endocrine or pancreatic assessment settings.

Doctors interpret the stimulated C-peptide result in relation to the simultaneously measured glucose level. An apparently low C-peptide value may have a different meaning when the patient's glucose is low than when glucose is adequately elevated. Kidney impairment can increase circulating C-peptide because the kidneys help remove it from the body. These factors make specialist interpretation essential.

Preparation Before Test

This is a supervised stimulation test and should be performed only with a valid medical prescription and according to the protocol approved by the diagnostic centre. The exact fasting duration, glucagon dose, route of administration and blood collection times can vary between laboratories and clinical circumstances. Patients must follow the instructions provided by Focus Diagnostics and their referring doctor.

• Fasting may be required, commonly overnight, depending on the prescribed protocol.
• Plain water may generally be permitted during fasting, but confirm this with the testing centre.
• Do not stop insulin, diabetes tablets or any other prescribed medicine unless the treating doctor specifically instructs you to do so.
• Inform the medical team about diabetes, kidney disease, liver disease, pancreatic disorders and previous episodes of severe low blood sugar.
• Provide a complete list of medicines, supplements and recent treatments.
• Tell the staff if you have previously experienced an adverse reaction to glucagon.
• Inform the centre if you are pregnant, may be pregnant or are breastfeeding.
• Arrive early enough for registration, baseline assessment and supervised sample collection.

Because glucagon can cause temporary nausea, vomiting, abdominal discomfort, headache or changes in blood glucose, patients are monitored during the procedure. The test should not be attempted at home. The medical team may check baseline glucose and confirm whether it is safe to proceed. After completing all scheduled samples, the patient should follow the staff's instructions regarding food, medicines and departure from the centre.

Test Procedure

A trained healthcare professional first confirms the patient's identity, preparation and medical history. A baseline blood sample is collected for C-peptide and usually for glucose. Glucagon is then administered by the authorised clinical team using the prescribed dose and route. Additional blood samples are collected at specific post-stimulation intervals.

Sampling schedules are not identical everywhere. Some protocols use a single post-glucagon sample, while others collect samples at multiple intervals. The exact procedure used for an individual patient must match the physician's request and the laboratory's validated protocol. Patients should remain at the centre until monitoring and all scheduled collections are complete.

The blood specimens are processed and analysed using a laboratory immunoassay. The baseline and stimulated results may be reported individually, together with the relevant reference information. The report must be interpreted using the assay method and decision limits adopted by the performing laboratory.

Normal Reporting Time

The expected reporting time for a C-Peptide Stimulation by Glucagon test is generally one to three working days after all required samples have been collected. Actual availability may vary according to laboratory workflow, sample stability, quality-control checks, holidays or whether the analysis is performed at a specialised reference laboratory.

Patients should confirm the estimated delivery time while booking. Dynamic tests involve multiple labelled specimens, and every sample must be correctly timed and processed. If a specimen does not meet quality requirements, the laboratory may contact the patient or referring doctor before releasing the report.

Who Should Take This Test?

This test is intended for selected patients following evaluation by a physician, diabetologist or endocrinologist. It may be appropriate for people whose natural insulin production needs to be quantified more accurately than with a routine fasting measurement.

• People with diabetes whose exact diabetes type remains uncertain.
• Patients in whom type 1 and type 2 diabetes need further differentiation.
• Adults suspected of having latent autoimmune diabetes.
• Patients with long-standing diabetes whose remaining beta-cell function needs assessment.
• People with low or borderline fasting C-peptide results requiring functional evaluation.
• Selected patients being assessed for pancreatic beta-cell reserve.
• Patients with pancreatic disease when insulin-secretory capacity is clinically relevant.
• People undergoing specialist evaluation before major diabetes treatment decisions.

The test is not a routine screening investigation for everyone and should not replace fasting blood glucose, post-meal glucose, oral glucose tolerance testing or HbA1c when those tests are clinically appropriate. A healthcare professional should decide whether stimulated C-peptide testing will answer a meaningful clinical question.

Understanding the Results

A measurable rise in C-peptide after glucagon generally indicates that the pancreatic beta cells retain some ability to produce insulin. A reduced or absent response may suggest limited beta-cell reserve or severe insulin deficiency. However, there is no single universal cut-off suitable for every laboratory, patient or clinical purpose.

Interpretation depends on the baseline and stimulated C-peptide concentrations, glucose values, kidney function, duration of diabetes, current treatment and laboratory assay. A higher stimulated value does not automatically mean that diabetes is well controlled, and a lower value does not independently establish type 1 diabetes. Some people with insulin resistance may produce substantial amounts of insulin while still having elevated glucose.

Doctors may compare the findings with HbA1c, fasting and postprandial glucose, diabetes-related autoantibodies such as GAD antibodies, renal function tests and the patient's medication history. Treatment must never be started, stopped or modified solely on the basis of an online explanation or without consulting the treating doctor.

Detailed Information

C-peptide is useful because it acts as a marker of endogenous insulin secretion. Injected insulin does not contain C-peptide, so the test can help assess natural pancreatic secretion even in many patients already receiving insulin. Nevertheless, factors such as severe hypoglycaemia, high glucose, reduced kidney clearance and certain medicines can influence the measurement.

Glucagon is a hormone that raises blood glucose and can stimulate insulin secretion when functional beta cells are present. In this test, it is used as a controlled stimulus rather than as a treatment for the underlying disease. Short-lived nausea is one of the more commonly recognised effects. Because individual risks differ, the procedure requires trained staff, appropriate monitoring and access to medical support.

Focus Diagnostics performs the test using established sample-identification, processing and quality-control procedures. Patients should bring their doctor's prescription, relevant previous reports and a list of current medicines. For accurate clinical interpretation, the final report should be reviewed by the referring physician or endocrinologist.